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ABSTRACT
EVALUATION OF ESSENTIAL OILS (STAY STRONG) FOR DAIRY CALVES
KELLY ANN FROEHLICH
2016
Stay Strong (SS, Ralco Inc., Marshall, MN) is a blend of essential oils (EO) and
prebiotic fiber technologies designed to promote immunity and stimulate appetite,
helping to diminish health challenges and stresses experienced by newborn calves.
Current feeding inclusion rates are unknown to achieve optimal performance in the first 8
weeks of life. The study objectives were to determine the optimal feeding inclusion rate
of SS when added to milk replacer (MR) to achieve optimal performance when compared
to a yeast cell wall (YCW). One hundred Holstein calves were blocked by birth date and
randomly assigned to 1 of 5 treatments. Treatments were: Control (C): a 24:20 MR, EO
mixed into 24:20 MR at a rate of 1.25 g/feeding (EO-0.5), 2.5 g/feeding (EO-1.0) or 3.75
g/feeding (EO-1.5), or 24:20 MR with an inclusion of YCW at a rate of 2 g/calf/feeding.
Calves were sourced from a commercial dairy farm where they were fed colostrum for
the first 2 d and then were transported to South Dakota State University (SDSU). The
24:20 MR was fed via bucket 2 x/d at a rate of 0.28 kg/calf/d for 14 d, increased to 0.43
kg/calf until 35 d and were reduced to 1 x/d at 36 d to facilitate weaning at 42 d.
Decoquinate was added to MR at 37.8 g/ton for coccidiosis control. Calves were housed
in individual Calf-Tel hutches bedded with straw with ad libitum access to a 20% CP calf
starter (CS) and water. It was hypothesized that calves supplemented with the medium
dose (EO-1.0) of the commercial EO would be most optimal, and in general calves
supplemented with commercial EO would have improved growth, health, and immunity
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compared to calves not supplemented. All data was analyzed using PROC MIXED in
SAS as a completely random design. Calves fed EO-0.5 demonstrated greater ADG
(0.65, 0.71, 0.64, 0.64, and 0.63 kg/d for C, EO-0.5, EO-1.0, EO-1.5, and YCW,
respectively) through 56 d compared to calves fed EO-1.0 and YCW, and tended to be
greater for C and EO-1.5. Total body weight gains (36.8, 39.9, 35.5, 35.8, and 35.4) were
greater for calves fed C and EO-1.5 compared to calves fed EO-1.0 and YCW. Body
length gains were greater for calves fed EO-0.5 compared to calves fed other treatments.
Hip width gains were similar among treatments. Wither height gains were greater for
calves fed EO-0.5 compared to calves fed the remaining treatments. Hip height gains
were also increased for calves fed EO-0.5 compared to calves fed C, EO-1.0, and EO-1.5,
while being similar for calves fed YCW. These results demonstrate that supplementing
EO-0.5 (1.25 g/calf/d) in a 24:20 MR may be optimal to enhance growth rates compared
to calves fed a 24:20 MR and a 24:20 MR containing YCW technology or other inclusion
rates of EO.
Keywords: Calf, essential oils, yeast cell wall
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CHAPTER 1: LITERATURE REVIEW
INTRODUCTION
Animal agriculture is under increasing scrutiny as social pressures and new laws
have prohibited and restricted the use of antibiotics in animal production. These social
changes are severely impacting agriculture on the treatment and prevention of illnesses in
livestock. Dairy calves in particular are feeling the impact. Raising calves is both
expensive and labor intensive. Successful calf rearing programs are designed to grow
fast, healthy calves that are weaned at a young age to be the most economical. This
naturally puts a lot of stress on a newborn animal.
In the past, it was not uncommon to supplement milk replacer (MR) fed to calves
with antibiotics to combat these stresses and prevent any illnesses that might naturally
occur. There have been numerous studies demonstrating the benefits of adding antibiotics
in MR including increased gains, feed consumption, and decreased scours, mortality, and
protein requirements (Morrill et al., 1976). However, antibiotic supplementation in MR
is becoming more difficult as new FDA laws restrict the use. As an antibiotic alternative,
many new technologies are being studied, to decrease calf morbidity and mortality, and
include nutritional additives such as essential oils (EO) or microbial additives, such as
yeast. Many of these technologies show promising benefits that could improve calf
performance, health, and immunity.
ESSENTIAL OILS
Essential oils are a diverse group of secondary plant metabolites that contain
naturally occurring volatile components that support smell and taste of plants
(Calsamiglia, et al. 2007). In nature, EO play an important role in allelopathic
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communication between plants, attracting insects for pollination and dispersal of seeds,
helping to deter herbivores by reducing their appetite for the plant, and also may act as
antibacterials, antivirals, antifungals, insecticides or herbicides (Miguel, 2010). They are
defined as a product obtained from a plant or some parts through hydrodistillation, steam
distillation, or dry distillation, without heating by a mechanical process (Miguel, 2010).
Typically, EO are classified into two specific chemical groups, terpenoids (most
common) and phenylpropanoids, which are derived from different metabolic precursors,
contributing to more than 15,000 unique components (Miguel, 2010, Calsamiglia, et al.
2007).
Essential oils offer unique properties that could be a huge potential benefit for
animal agriculture. One such potential benefit that has a gained a lot of attention, is the
antibacterial properties. There is excitement that EO could be a potential mechanism to
improve feed efficiency, nutrient utilization, and animal health as an alternative to
antibiotics. However, at this point there is still a need for more research to provide
information for practical feeding recommendations. Most studies conducted have been
conducted using in vitro settings with very limited research in vivo. Complicating matters
more, differences in EO efficacy varies depending on what part of the plant is harvested,
time of year, where it was grown, and chemical type (chemical structure) (Calsamiglia, et
al. 2007). Inconsistencies of results also arise between research trials due to differences
involving diet, dosage rates, and animal management. As will be reported in the
following section, this literature summarization of some the important EO properties and
studies outlining EO potential benefit for animal agriculture.
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Antibacterial Modes
Contrary to their name, EO are not true oils, but are lipids. The hydrophobic
nature of EO contributes to its antimicrobial properties. It is through antimicrobial
properties that allows the alteration of bacterial growth and bacterial metabolism. A
couple modes of action have been identified, and is not likely caused by one specific
mode, but several target areas in the bacterial cell (Benchaar et al., 2008, Dorman and
Deans, 2000).
Essential oils have a high affinity for the lipid components in the bacterial cell
membranes. This affects cell membrane processes and thought to cause interruptions in
processes, such as electron transport, ion gradients, protein translocation,
phosphorylation, and other enzyme-dependent reactions (Dorman and Deans 2000).
One such reaction involves conformational changes in bacterial cell membrane
structure causing loss of membrane stability. It is hypothesized this happens when the EO
accumulates in the lipid bilayer of the bacteria cell membrane resulting in fluidification
and membrane expansion, causing the membrane to become leaky and decreasing the
transmembrane ionic gradient (Griffen, et al. 1999). This loss of membrane stability
affects a wide range of microorganisms including gram-positive (GP) and gram-negative
(GN) bacteria however, GP bacteria are more sensitive to EO. It is thought (GN) bacteria
are less susceptible because the outer cell wall is hydrophilic, thereby preventing
lipophilic essential oils from penetrating this barrier (Benchaar et al., 2008, Calsamiglia
et al., 2007). This interaction and subsequent loss of membrane stability typically does
not result in bacterial cell death, but results in slowed bacterial growth, which causatively
also affects the rumen fermentation profile (Griffen, et al. 1999).
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Oregano
Origanum vulgare, also known as oregano, is one well known EO that is shown
to disrupt bacterial cell membrane ion gradient, inhibiting both GP and GN bacteria
(Helander et al., 1998, Dorman and Deans 2000). The active components of oregano are
thymol and carvacrol, which chemically are a terpenoid with a phenolic structure. It has
been suggested that phenolic compounds, such as thymol and carvacrol, have effective
antimicrobial activity due to hydroxyl groups in the phenolic structure (Benchaar et al.,
2008). These active components are thought to disrupt the bacterial cell membrane in
several different ways. One study demonstrated that the proton motive force was
disrupted, and that the H+ and K+ ion gradients were dissipated affecting intracellular
ATP processes (Benchaar et al., 2011). Another proposed mechanism is similar to that of
ionophore antibiotics involving the hydroxyl group acting as a trans-membrane proton
carrier (Benchaar et al., 2011).
Essential oils, such as oregano that have active components containing phenolic
structures have been shown to be highly effective against specific microorganisms
(Dorman and Deans 2000, Benchaar et al., 2008), and has been well documented in many
lab based settings. One study conducted by Helander et al. (1998) reported that oregano
inhibited GN bacteria, such as Escherichia coli, and Salmonella tryphimurium. This is
further supported by Marino et al. (2001), who reported that oregano not only inhibited
GN Escherichi coli and Salmonella tryphimurium, but also Proteus mirabilis, Pro.
Vulgaris, Serratia marcescens, Yersinia enterocolitica, Pse. Fluorescens and Pse. Putida.
Oregano was shown to have inhibitory effects against a wide range of bacteria including
GP bacteria, such as Micrococcus sp., Sarcina flava, S. aureus, B. licheniformis, B.
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thuringiensis and L. innocua. Furthermore, compared to other EO, oregano was the most
effective and in high concentrations (800 ppm) caused 100% inactivation of all the tested
bacteria (Marino et al., 2001). It has been suggested as well, that certain EO may have the
ability to inhibit parasites, such as Cryptosoridium, coccidia, and nematodes (Benchaar,
et al. 2007).
Bampidis et al. (2006) conducted an in vivo study using calves that exhibited
Escherichia coli scours. Administration of dried oregano leaves in a liquid solution, may
be as effective in the treatment of E. coli scours, as an oral solution of neomycin sulphate.
In this study, calves were treated with either 10 mg of neomycin sulphate per kg of calf
weight or 10 mg of oregano per kg of calf body weight per 24 hours with results
indicating no significant differences in overall scouring days or calf mortality (Bampidis,
et al. 2006). These results should be interpreted with care as administration of oral plant
components could have the possibility of controlling a wide range of microorganisms,
that could also cause an imbalance in normal gut microorganisms. Potentially allowing
pathogens an opportunity to become established in the gut with detrimental results
(Dorman and Deans 2000). More research needs to be conducted to elucidate the optimal
EO inclusion rates that are effective at controlling various pathogens without inhibiting or
consequentially affecting other beneficial gut organisms or processes.
High dosages of EO, such as oregano and its major constituents (carvacrol and
thymol), has been shown to inhibit rumen microbial fermentation. In an in vitro study
conducted by Busquet et al. (2006), high dosage (3,000 mg/L) of oregano oil resulted in
decreased rumen total concentration of volatile fatty acids (VFA), ammonia N, and an
increase in ruminal pH, and this was true for almost all of the EO evaluated. These results
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indicate that EO, such as oregano oil, may be detrimental to rumen microbial
fermentation at high dosages (3,000 mg/L), but at marginal (300 mg/L) and low dosages
(3 mg/L) can be administered safely without inhibiting rumen fermentation (Busquet, et
al. 2006). These results correspond well with other in vitro studies Castillejos et al.
(2007) reported that a high dose (500 mg/L) of EO including oregano, decreased total
VFA concentrations, ammonia N, and increased ruminal pH, and acetate to propionate
ratios. Lower dosages (5 and 50 mg/L) had no effect on ammonia N, rumen pH, acetate
to propionate ratios, but did increase concentration of VFA (Castillejos, et al. 2007).
Testing the pure components of oregano, such as thymol also yields similar
results in terms of rumen fermentation (Calsamiglia et al., 2007). It was suggested that
ruminal deamination was inhibited when there was an accumulation of AA and a
reduction in ammonia N concentrate in an in vitro study incubated with casein in rumen
fluid containing thymol (1000 mg/L). Overall, there seems to be a consensus that thymol
demonstrates similar results in vitro as oregano. At higher doses, thymol can affect
overall nutrient digestion, decrease volatile fatty acid production, decrease ammonia N
concentrations and that overall microbial metabolism within in the rumen is inhibited. It
has been suggested that an optimal dose of thymol ranges approximately between 50 and
500 mg/L (Calsamiglia et al., 2007).
Carvacrol, the other main active component of oregano, has been suggested to
either inhibit proteolysis or stimulate peptide lyses. An in vitro study using higher doses
of carvacrol (300mg/L) decreases acetate-to-propionate ratios, VFA production, and
increases pH and butyrate proportion. Lower doses (2.2 mg/L) decreased large peptide
concentrations and increased ammonia N concentrations (Calsamiglia et al., 2007).
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In both the pure components of oregano and oregano itself, in vitro studies
demonstrate similar results in that high dosages can be inhibitory to ruminal
fermentation. At moderate doses, there can be beneficial effects, however it is hard to
quantity what that optimal dose should be. The optimal dosage maybe dependent on type
of diet fed to the animal and has been suggested that pH can play a role. The
antimicrobial effect of thymol has shown pH dependency, the lower the pH (6.5 versus
5.5) the more efficacious the effect. Furthermore, the percentage of active ingredients in
oregano (carvacrol and thymol) are dependent on specific cultivar and processing
methods. The chemical structures of thymol and carvacrol are different and these
variations in chemical structures can affect results (Calsamiglia et al., 2007).
Essential oils and calves
Very limited EO research exists in vitro and even less in vivo results are available
in dairy calves. Published results among projects are variable but shows many promising
benefits, however more research needs to be done on optimal dosage and routes of EO
supplementation. Hill et al. (2007) reported improved average daily gains (ADG), calf
starter intake (CS) and efficiency in pre-weaned calves fed a commercial blend of
essential oils. There were two studies conducted. Study one fed calves either an all MR or
a MR with 45% of the crude protein from soy protein with or without the mix of EO. In
study two, calves were fed with or without EO in the CS. The MR was formulated to be a
20:20, and the CS was formulated to be 18% CP. All inclusion of EO was fed a 0.05% of
either the CS or MR or both. Calves were less than seven days old when enrolled in the
trial and were weaned at 42 days of age. At the conclusion of both studies, calves
supplemented with the commercial blend of EO had improved body weight gains, CS,
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and feed efficiency (FE) compared to calves that were not fed EO. It was also noted that
inclusion of the EO in both the CS and MR had additive effects on calf performance in
improved body weight gains and feed efficiency (Hill et al., 2007).
Santos et al. (2015), reported no increase in calf performance or health when
calves were supplemented with a commercial EO blend. In this study, neonatal calves
were fed a 20:15 MR and a 26% crude protein CS and were assigned to one of three
treatments: 1) Control with no added EO to MR or CS; 2) MR supplemented with 400
mg/kg of EO; and 3) EO supplemented at 200 mg/kg in both MR and CS. The authors
reported no treatment differences in feed intake, body weight, structural gains, ADG,
blood metabolites (plasma β-hydroxybutyrate and glucose), fecal scores, and counts of
intestinal microorganisms (enteboracteria and lactic acid bacteria). Rumen fluid samples
collected from the calves demonstrated no difference in ruminal pH, VFA, acetate to
propionate ratio, or counts of protozoa, cellulolytic and amylolytic bacteria. However,
ammonia-N concentrations were significantly higher in calves supplemented with EO in
MR and CS. It was concluded that addition of EO in the MR, CS, or both did not hinder,
but also did not improve the health or performance of dairy calves (Santos et al., 2015).
In a post-weaned study, Vakili et al. (2013) supplemented Holstein calves fed a
high concentrate diet with either thyme or cinnamon EO. This study utilized three
treatments: 1) control with no EO supplemented to the diet; 2) control diet with 5 grams a
day per calf of thyme EO added; and 3) control diet with 5 grams a day per calf of
cinnamon EO added. Diets fed were a total mix ration (TMR) composed of 15% alfalfa
hay and 85% concentrate and formulated to meet NRC (1996) nutrient requirements.
Similar to the study conducted by Santos et al. (2015) in pre-weaned calves Vakili et al.
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(2013) reported no effect on calf performance in ADG, FE, DMI, blood metabolites
(glucose, urea N, triglyceride, total cholesterol, β-hydroxybutyrate, alanine
aminotransferase, aspartate aminotransferase). Rumen fermentation was also similar
among treatments for ruminal pH, ammonia nitrogen, and total VFA. There was however,
a decrease in molar proportions of calves supplemented with EO compared to control
calves in acetate to propionate ratios, and acetate levels. Molar proportions of propionate
were increased for calves supplemented with EO compared to control, Butyrate
proportions were also significantly increased for calves fed the cinnamon EO over the
control calves (Vakili et al., 2013).
PREBIOTICS
Prebiotics are non-digestible food additive that promote the growth and activity of
specific gut microbes that beneficially affect the host (Samanta et al., 2012 and Uyeno et
al., 2015). Specifically, prebiotics are carbohydrate biomolecules in the form of fructans.
There are a variety of biomolecules that can be considered as a prebiotic, which can be of
plant origin, or obtained from microbial additives such as yeast. These molecules can be
further classified into a variety of subcategories, such as oligosaccharide, polysaccharide,
or trisaccharide (Samanta et al., 2012). Some examples of oligosaccharides used in in the
livestock industry are Mannan-oligosaccharide (MOS), or Fructooligosaccharides (FOS),
galactosyl-lactose is a trisaccharide, and a well-known polysaccharide is inulin.
In ruminants, rumen microbes can ferment prebiotics and utilize it as a source of
energy. The non-digestibility of prebiotics ensures that the microbes receive it as an
energy source and is used directly by the host. This subsequently can cause an alteration
in the microbial population activity and composition which can result in other effects,
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such as drop in pH and increased gas production (Papatsiros et al., 2013). Furthermore,
these prebiotics when fed have demonstrated increases in N retention, beneficial
microflora, weight gain in calves, decreased rumen ammonia nitrogen, and better fecal
consistency in calves (Samanta et al., 2012). It has been suggested, that prebiotics can be
advantageous to ruminants when exposed to a variety of stresses, such as transportation,
weaning, etc. that can result in a variety of adverse health events. Prebiotics promote the
growth and activity of healthy gut microflora excluding pathogens that can reduce the
adverse health events caused by stress, such as diarrhea, depression of growth and feed
intake (Samanta et al., 2012 and Uyeno et al., 2015). It has also been shown that
prebiotics can reduce the colonization of gut pathogens such as Salmonella and E. coli
(Papatsiros et al., 2013), as well as, increase concentrations of immunoglobulins
(Heinrichs et al., 2009). These characteristics specifically can have beneficial results in
neonates in which the gut microflora is adapting and developing under a variety of
stresses.
Feeding oligosaccharides to calves has shown similar results as supplementing
antibiotics in milk replacer (Quigley et al., 1997 and Donovan et al., 2002).
Supplementation of galactosyl-lactose increased body weight gain, feed efficiency and
decreased severity of scours when supplemented to calf MR, contributing to increased
intestinal health (Quigley et al., 1997). In a commercial prebiotic mix fed to calves
tended to increase beneficial bacteria, such as Lactobacilli and increased fecal IgA, which
suggested an increased intestinal health (Heinrichs et al., 2009). Similarly, MOS, and
FOS have shown promising benefits in calf health and performance (Uyeno et al., 2015).
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Modes of Action
Prebiotics promotes its benefits through a variety of mechanisms. Consumption
of prebiotics results in the production of short chain fatty acids (propionate, acetate,
butyrate) and lactic acid which decreases luminal pH. Decreased luminal pH is also
thought to play an important role in enhancing mineral absorption, as some minerals,
such as calcium has a higher solubility in lower pH and increases the gradient across the
epithelium. It is hypothesized that the feeding of prebiotics interacts with the intestinal
tight junctions in the epithelium increasing the permeability for mineral absorption.
Calcium, magnesium, iron, and zinc have all demonstrated increased absorption with the
feeding of prebiotics (Samanta et al., 2012).
Production of butyric acid promotes stimulation of goblet cells and subsequent
increased mucous production in the intestines, which plays an important role in immune
defense. Butyric along with lactic acid production plays an important role in gut
epithelium development, increasing length and width of crypts and subsequent nutrient
absorption (Samanta et al., 2012).
Consumption of prebiotics has also been shown to increase beneficial bacteria in
the intestine such as Bidobacteria and Lactobacilli. The production of these bacteria are
beneficial due to their ability to produce short chain fatty acids, reduce gut pH, ferment
non-digestible carbohydrates, and stimulate immunoglobulin production (Samanta et al.,
2012). These beneficial bacteria exclude gut pathogens through competitive exclusion by
suppressing growth, reducing toxic fermentation products. This is accomplished by
preventing the adhesions of pathogens to mucosa by competing with the sugar receptors
(Samanta et al., 2012 and Papatsiros et al., 2013).
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Mannan-oligosaccharide (MOS)
Mannan-oligosaccharide is a mannose sugar that is derived from the cell wall
fragments of yeast, such as Saccharmyces cerevisiae. It is known for its ability to adsorb
pathogens with type-1 mannose-specific fimbriae that are found in many GN bacteria,
such as Escherichia coli and Salmonella. This increases competition for binding sites on
the intestinal epithelium, decreasing the pathogens ability to colonize the gastrointestinal
tract (Heinrichs et al., 2003 and Brady et al., 2015). This allows MOS with the ability to
help improve immunity, performance, and health of dairy calves.
There has been varying results published in literature on calves supplemented
with MOS. Heinrichs et al. (2003), found that when Holstein calves were supplemented
with MOS they performed similarly as calves supplemented with antibiotics. In this
study, calves were randomly assigned to one of three treatments: 1) control 20:20 all MR;
20:20 all MR with 400g/440 kg of neomycin + 200 g/440 kg of oxytetracycline; and 3)
20:20 all MR with 4 g calf/ d of Bio-Mos supplemented. It was found that calves
supplemented with antibiotics and MOS had a greater probability of having normal feces
throughout the study meaning less scours overall compared to control calves. There was
no difference in ADG or FE among the three treatments. However, calves supplemented
with MOS had significantly higher grain intakes during week six (when calves were
weaned) than that of calves supplemented with antibiotics. Greater feed intake did not
affect growth performance such as body weights and body parameters (hip width, wither
height, heart girth, hip height) were similar among treatments. The authors reported no
significant differences in metabolic problems between calves, blood urea N and total
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blood protein between treatments. It was concluded that MOS could be as effective as an
antibiotic alternative in calf MR (Heinrichs et al., 2003).
Similarly, Terre et al. (2007), found that supplementing a MOS product
stimulated an increase in CS intake after weaning, as did Heinrichs et al (2003), but did
not improve growth rates. In this study, Holstein calves were enrolled in an enhancedgrowth feeding program in a group pen. Calves were assigned to one of two pens; pen
one calves were fed MR supplemented with 4 g/d of Bio-Mos, pen two was control
calves just fed MR with no supplementation. Calf performance throughout the trial was
similar between treatments. Body weight, and ADG, and gain: feed was not significantly
different between treatments (P > 0.05). Dry matter intake of MR and CS were similar
with the exception of MOS supplemented calves having higher CS intake compared to
control calves right after weaning. The incident of loose feces or scours between
treatments were similar as well as total fecal counts of Escherichia coli and Clostridium
perfringens. Numerically, the probability of observing presence of Cryptosporidium in a
fecal smear was lower for calves supplemented with MOS compared to control calves in
the first two weeks of the study. However, in week three the control calves had
numerically lower presence of Cryptosporidium than calves supplemented with MOS.
Lastly, there was no difference in serum haptoglobin concentrations between treatments.
The authors concluded that supplementing calves with MOS did increase CS intake after
weaning, but did not affect the growth performance, nor reduced fecal bacterial counts in
calves (Terre et al., 2007).
Unlike Heinrich et al (2003) and Terre et al. (2007), Ghosh and Mehla (2012)
reported that supplementing cross-bred dairy calves with 4 g/d of Bio-Mos compared to
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control calves increased body weight gain. Feed intake overall was increased throughout
the study, however the results were not separated by pre- and post-weaning stages so it is
difficult to ascertain if similar patterns were observed as reported by Heinrich et al (2003)
and Terre et al. (2007) were intake was increased just after weaning. Fecal scores for
calves supplemented with MOS was significantly lower compared to control calves and
unlike Terre et al. (2007), there was a significant decrease in fecal coliform counts
(Ghosh and Mehla, 2012).
It has also been hypothesized that feeding of MOS to dry cows pre-calving or
supplementing calves with MOS in colostrum could improve immunity. Franklin et al.
(2005) reported that supplementation of periparturient dairy cows with MOS resulted in a
tendency for calves to have increased serum protein concentrations (passive transfer)
from birth to 24 hours of age. Supplementing the ration with MOS enhanced the cow’s
immune response to vaccination such as rotavirus, which resulted in the calves receiving
better antibodies against rotavirus. It was proposed that MOS supplementation to
periparturient cows could enhance immunity transfer to calves leading to better calf
immunity when born, which could result in decrease treatment costs (Franklin et al.,
2005). Increased serum protein concentrations were not observed when calves were
supplemented with 30 g of MOS in the colostrum. Colostrum supplementation with MOS
actually resulted in negative effects. Brady et al. (2015) recommended not to supplement
MOS in calf colostrum. In that study, MOS supplementation in fresh maternal colostrum
led to lower apparent efficiency of IgG absorption and reduced serum IgG concentrations
compared to control calves (Brady et al., 2015). These results are similar to Robichaud et
al. (2014), who reported that MOS supplementation to colostrum calf replacer resulted in
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similar apparent efficiency of absorption of IgG and serum IgG concentrations compared
to control. It was also reported that there were no effects on incidences of diarrhea,
pneumonia, survival, or ADG in calves supplemented with MOS in colostrum replacer
between birth and weaning (Robichaud et al., 2014).
Fructo-oligosaccharides (FOS)
Fructo-oligosaccharide is a soluble fiber that is composed of several β-(1,2) or β(1,6) linked fructose residues. It is obtained from the partial hydrolysis of inulin, a
carbohydrate energy source for plants most often sourced from chicory root (Franck,
2006). Fructo-oligosaccharide is known to stimulate the production of beneficial bacteria
in the gut, including Bifidocteria and Lactobacilus, which can ferment FOS to short chain
fatty acids (Quigley et al., 2002, Grand et al., 2013, and Jenkins et al., 1999). Increased
production of short chain fatty acids is used as a source of energy, can enhance mucosal
structure, and prevent the colonization of pathogens, such as Clostridium difficile (Grand
et al., 2013 and Donovan et al., 2002).
In rat and human studies, FOS or oligofructose, has shown clear benefits in
mineral absorption and bone mineralization. Supplementation of FOS demonstrated that
calcium and magnesium absorption is enhanced (Franck et al., 2006). It has also been
shown that FOS increases calcium balance, true and apparent intestinal absorption and
mineral density in growing rats (Morohashi, 2002).
In calves, studies evaluating FOS supplementation reported that calf performance
can be enhanced as a result of the modification of microbial fermentation activity,
possibly as an antibiotic replacement, and a useful tool in times of stress (Grand et al.,
2013, Quigley et al., 2002, and Donovan et al., 2002). Grand et al. (2013), studied the
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effects of different FOS dosages on the growth performance, carcass characteristics and
fecal concentrations of short chain fatty acids on Holstein cross veal calves. Calves were
fed a MR containing 5% soluble wheat proteins and supplemented with either 0, 3, or 6
g/d of FOS. Body weight, cold carcass weight, DMI, ADG, and feed conversions were
similar between treatments. Numerically, calves supplemented with FOS had a reduction
in feed conversion and increased carcass weight, and ADG. There was also an
observation of an overall increased production of short chain fatty acids with an increased
percentage of butyrate and a decrease in acetate production in calves supplemented with
FOS compared to control, however not statistically significant. It concluded that
supplementation of FOS in MR allowed enhanced growth parameters (Grand et al.,
2013).
Grand et al. (2013) reported results similar to Kaufhold et al. (2000) who fed veal
calves supplemented with or without FOS. Kaufhold et al. (2000), reported that calves
supplemented with 10 g/d of FOS tended to have greater weight gains compared to
control calves. Feed intakes among the two treatments were similar. Instead of studying
carcass and short chain fatty acids in feces, Kaufhold et al. (2000) was interested in
metabolic and endocrine functions of calves supplemented with FOS. It was reported that
FOS supplementation decreased post-prandial glucose and increased insulin
concentrations in very small amounts when calves were given lactose. It was concluded
that FOS had similar effects on the metabolic and endocrine traits as humans with
diabetes mellitus and that FOS may aid in coping with insufficient control of glucose
metabolism (Kaufhold et al., 2000).

17

Quigley et al. (2002) studied the effects of feeding spray-dried animal plasma
with or without the addition of FOS on the growth and health of calves. This study was
conducted into two separate experiments in which Holstein calves were used. Calves
were fed MR in study one with 0 to 20% of the crude protein being spray-dried animal
plasma and experiment two was with 0 to 16% of the crude protein containing spraydried animal plasma. Both studies had treatments containing 30 or 60 g of additive that
had FOS added that contained either bovine serum or whey protein. In both studies,
calves fed milk with FOS had fewer scour days, and improved fecal scours compared to
calves fed control. One experiment reported increased body weight gain and subsequently
feed efficiency when feeding FOS compared to control fed calves (Quigley et al., 2002).
IMMUNITY
Immunity plays an important role in calf health and is often an overlooked area of
research. Immunity is the normal function of the immune system that helps to keep an
individual healthy by maintaining homeostasis by recognizing and attacking foreign
substances that disrupts balance. The immune system can be classified into two distinct
types: innate and acquired/adaptive immune responses. Innate immune system is referred
to as the first line of defense and is non-specific in nature. In neonates, the innate immune
system is the most important, because it is what the calf is born with. Development of the
calf is required to develop an acquired/adaptive immune system. Innate immune system
uses mechanisms, such as external defenses, which include the use of physical barriers,
like skin, mucous, etc. It can use internal defenses, such as phagocytic cells such as
macrophages. Both external and internal defenses are used to keep and clear foreign
substances from the body. The innate immune cells can also release signaling proteins,
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such as cytokines, that help connect to the adaptive immune response (Mak et al., 2014
and Lippolis 2007).
The adaptive immune system is the second line of defense and is considered
specific in nature because it is designed to recognize and remember specific pathogens.
Adaptive immune response is triggered when signals are received from the innate
immune system (cytokines) when the system is unable to remove or overcome a threat.
Adaptive immunity is divided into both passive and active immunity. Active immunity is
developed upon contact with an antigen, pathogen, or vaccination which can be further
divided into humoral and cell-mediated immunity. Humoral immunity is composed of Bcells that are produced and mature from the bone marrow, that become antibodyproducing or memory cells. The cell-mediated immunity is composed of T-cells that
mature in the thymus to give rise to T-helper or T-cytotoxic cells. B-cells are specialized
to recognize whole antigens, whereas, T-cells recognize fragments of antigens presented
on the major histocompatibility complex molecules which are used to enhance immune
responses. Overall, active immunity uses humoral and cell-mediated approaches to
mature B-cells into making their own antibodies. (Mak et al., 2014 and Lippolis 2007).
Passive immunity is recognized as the transfer of antibodies to a non-immune
individual, such as antibodies received by a neonate from its mother. Compared to active
immunity, this is a relatively fast immunity development. Passive immunity is vitally
important for neonatal calves as they are born agammaglobulinemic (no antibodies).
Neonatal calves are unique in that they receive no maternal antibodies
(immunoglobulins) via placental transfer. Immunoglobulins are taken up mostly across
the gut epithelium by receiving colostrum, making it imperative that quality colostrum is
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received when they are born (Pastoret et al., 1998). Passive immunity is an evolutionary
response that has developed as antibodies, such as immunoglobulin G (IgG), may take as
long as 6-12 months to develop adequate amounts in serum and secretory Igs to be
produced by the newborn (Mak et al., 2014).
Immunoglobulins (Ig)
Antibodies or immunoglobulins are glycoproteins members of the
immunoglobulin super family. Their basic structure is composed of two light chains and
two heavy chains, which come together to form a Y shaped molecule. These molecules
have two Fab sections that retains antibodies antigen-binding ability and one Fc region
that is considered the tail of the antibody. This Fc region does not bind to antigens, but
instead recognizes and binds to Fc receptors on innate cells, and controls antibody
effector functions. There are four antibody effector functions which include
neutralization, classical complement activation, oponization, and antibody-dependent
cell-mediated cytotoxicity (ADCC) (Mak et al., 2014). When an infection or vaccination
occurs there is a humoral immunity response in which immunoglobulins are secreted and
the foreign entity or pathogen is eliminated or neutralized through the effector functions.
There are five different immunoglobulin isotypes- IgG, IgA, IgE, IgD and IgM. Each
type has different biological functions and physical properties; typically IgG, IgA, and
IgM are found in serum and IgD and IgE are only found in serum in low concentrations
(Cervenak and Kacskovics, 2009).
Immunoglobulin G (IgG)
Immunoglobulin G is the most common immunoglobulin isotype found in tissue
and blood with a long half-life (Cervenak and Kacskovics, 2009). There are three
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recognized subclasses recognized in bovine; IgG1, IgG2, and IgG3 (Pastoret et al., 1998).
The IgG class uses a mix of antibody effector functions including opsonization, ADCC,
and classical complement activation to eliminate pathogens. Opsonization and ADCC are
exerted by the FcγR- bearing cells, such as phagocytes and lytic cells, that has a high
affinity to IgG1 and IgG3 subclasses (Mak et al., 2014).
Calves are born agammaglobulinemic and must receive maternal antibodies
through colostrum. Bovine colostrum is specifically high in IgG (Pastoret et al., 1998),
and has a 90% absorption rate (Roy, 1979). Specifically, colostrum is composed mainly
of IgG1 subclass, which binds to FcRn (neonatal Fc receptor) antibodies with a high
affinity. This FcRn receptor is important in transporting maternal immunity and protects
IgG from fast degradation until the calf is able to develop their own antibodies (Cervenak
and Kacskovics, 2009).
Ingestion of colostrum is time dependent and it is important for a calf to receive
colostrum before gut “closure” and before establishment of gut microflora, otherwise
bacteria can be absorbed the same way as maternal IgG (Roy, 1979). It is critical for
calves to receive colostrum for adequate IgG absorption within the first 24 hours. Calves
are 74 times more likely to die in the first 3 weeks if they do not receive colostrum
(Hulbert and Moisa, 2015). Furthermore, calves that do not receive adequate amounts of
colostrum with low IgG absorption are said to have a failure of passive transfer.
Successful passive transfer is defined as having a serum IgG reading of above 10 mg/mL
by 48 hours of age. Generally, higher serum IgG levels are associated with healthier
calves that have lower morbidity and mortality rates (Barrington et al., 2001).
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Immunoglobulin A (IgA)
Immunoglobulin A is often considered the first line of defense when it comes to
immunoglobulins because it binds to pathogens at the mucosal surfaces, which are
common sites of pathogen attacks (Mak et al., 2014). It is found in a secretory form
referred to as secretory IgA (SIgA), such as tears, saliva, milk, and mucus, and is
produced in the gastrointestinal, urogenital, and respiratory tracts. Immunoglobulin A
uses neutralization by cross-linking microorganism and macromolecules to prevent
pathogens from attaching to the surface of epithelial cells at mucosal surfaces (Corthesy,
2013 and Mak et al., 2014). Low production of IgA is linked to a variety of recurring
gastrointestinal, respiratory infections and even allergies/asthmas in humans (Corthesy,
2013).
The serum concentration of IgA is found to be low and is lower in bovine
colostrum then IgG (Pastoret et al., 1998), but never less still important. When a calf
receives colostrum there is a high concentration of serum IgA but disappears quickly into
the intestinal lumen. High concentration of immunoglobulins (300 to 400 g Ig in first 48
hours) from colostrum regardless of isotype are associated with reduced calf mortality
and morbidity and is vitally important (Roy et al., 1979). Calves that receive no colostral
Igs will remain basically agammaglobulinemic until immune system develops leaving the
calf susceptible to infections and even death (Butler, 1969).

CONCLUSION
Milk replacer additives such as EO or prebiotics show many promising benefits to
increase calf health and performance with the out use of antibiotics. However, more
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research needs to be conducted to elucidate the optimal dosages, and the most efficacious
to enhance calf growth, performance, and health. Furthermore, it is important to
understand calf immunity and ways to improve immunity; either through feed additives
or changing the management of calves to reduce stresses. This literature review was to
illuminate the current research conducted to date leading well into the study presented in
the next chapter evaluating a commercial blend of EO and prebiotics, mainly oregano,
and how performance compares to prebiotics or calves not supplemented with either
additive.
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CHAPTER 2: EVALUATION OF STAY STRONG FOR DAIRY CALVES
INTRODUCTION
Neonatal calves often experience numerous stresses caused by being exposed to
pathogens eliciting various enteric and respiratory problems resulting in pre-weaning
deaths. The United States has a 7.8% mortality rate in pre-weaned heifer calves. Of these
mortality rates, 56.5% is attributed to scours and digestive problems and another 46.7% is
attributed to respiratory problems (USDA-NAHMS, 2007). Supplementing antibiotics in
MR has many benefits including reduction in mortality rates, scours and increased feed
consumption and gains (Morrill et al., 1977). However, increased FDA regulation and
public scrutiny makes the supplementation of antibiotics in MR quite difficult. It is
estimated that the treatment of respiratory and enteric problems in calves exceeds $250
million annually (Simmons and Bywater, 1991). This is of huge economic significance to
the industry, resulting in investigations for identifying alternatives to antibiotics.
One such alternative is the use of essential oils (EO). Essential oils are a diverse
group of secondary plant metabolites and contain naturally occurring volatile components
that support the smell and taste of plants (Calsamiglia et al., 2007). In nature, EO play a
role in attracting insects, and allelopathic communication in plants. Additionally, EO may
also act as antibacterials, antivirals, antifungals, insecticides, and herbicides (Miguel,
2010). Antibacterial is one of the most noted contributing feature of EO in animal
agriculture. It is this ability that has the potential to alter bacterial growth, by causing
conformational changes to membrane structures affecting cell membrane processes of
bacteria (Benchaar et al., 2007, Calsamiglia et al., 2007).
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Typically, EO have more of an effect on GP bacteria than GN bacteria due to the
cell membrane being less impermeable (Benchaar et al., 2007). However, certain EO
such as oregano have been shown to inhibit growth of several GN bacteria, including E.
coli (Marion et al., 2001). Bampidis et al. (2006), found that administration of an oral
oregano solution to calves with E. coli scours may be as effective as neomycin. Further
studies supplementing pre-weaned calves with EO have found increases in CS intake,
feed efficiencies, and body gains (Hill et al., 2007). As well as increase proportion of
beneficial microorganisms in the intestinal flora (Santos et. Al., 2015). As a result EO
show promising benefits as a potential feed additive to help reduce neonatal stresses,
while improving performance without the use of antibiotics. Thus, the objective of this
study was to determine optimal inclusion rate of a commercial EO mix to promote calf
growth, and health, when added to the MR of pre-weaned dairy calves compared to
calves fed a control or yeast cell wall (YCW) product. It was hypothesized that calves
supplemented with the medium dose (EO-1.0) of the commercial EO would be most
optimal, and in general calves supplemented with commercial EO would have improved
growth, health, and immunity compared to calves not supplemented.
MATERIALS AND METHODS
Calf Feeding and Management
This research project was conducted at the South Dakota State University (SDSU)
Animal Research Wing (ARW, Brookings, SD) from September 7 to December 8, 2015,
all procedures were approved by SDSU Institutional Animal Care and Use Committee
before the start of the study. One hundred Holstein calves were sourced from a
commercial dairy farm and were housed in Calf-Tel hutches bedded with straw. Calves
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were blocked by birth date and randomly assigned to 1 of 5 treatments. Treatments were:
Control (C): a 24:20 MR, EO mixed into 24:20 MR at a rate of 1.25 g/feeding (EO-0.5),
2.5 g/feeding (EO-1.0) or 3.75 g/feeding (EO-1.5), or 24:20 MR with an inclusion of
YCW at a rate of 2 g/calf/feeding. Essential oil was Stay Strong for dairy calves
manufactured by Ralco (Marshall, MN) and the YCW technology (Bio-Mos) was
manufactured by Alltech (Nicholasville, KY).
Prior to enrollment in the study, calves were tested for successful passive transfer
of colostrum, and bovine viral diarrhea (BVD). Successful passive transfer was
determined by serum samples that were collect via jugular puncture and were read for
total protein (TP) using a Brix refractometer. Calves with total protein greater than 5.5
g/dl were considered successful. Ear notch samples were submitted to South Dakota
Animal Disease Research and Diagnostic Laboratory (SDSU-ADRDL) for BVD testing.
Upon arrival, calves were castrated using an elastic ring (Animal Health International,
Greenly, CO) and vaccinated with Inforce 3 via intranasal (Zoetis; Florham Park, NJ).
Calves were fed colostrum before their arrival at SDSU for the first two d of life.
A 24:20 MR was fed at a rate of 0.28 kg/calf at each feeding (0630 and 1730 h) daily for
14 d via bucket, and then increased to a feeding rate of 0.43 kg/calf at 2x/d until 35 d.
Feedings were reduced to 1x/d at 36 d to facilitate weaning at 42 d. Decoquinate was
added to MR at 37.8 g/ton for coccidiosis control. A 20% CP pelleted calf starter (CS)
and water was offered ad libitum throughout the study. All MR and CS were sourced
from Hubbard Feeds Inc. (Mankato, MN). Intakes and refusals of CS were recorded daily
in the morning, and any MR refusal were also recorded. Both CS and MR samples were
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collected every two weeks and stored frozen (-20ºC) before being composited by month
and sent to Analab (Fulton, IL) for analysis.
Ovalbumin Vaccination
Calves were subjected to an ovalbumin (OVA) challenge, and were vaccinated in
the beginning of week three (21 d) and then given a booster on week six (42 d). Calves
were given 4 mL subcutaneously of an OVA solution in four, 1 mL injections to the side
of the neck to minimize abscesses. The OVA solution contained 4 mg of crystallized
OVA (Sigma Chemical, St. Louis, MO) suspended in a phosphate buffered saline (PBS).
The concentration of the OVA-PBS solution was 2 mg of OVA/ml of PBS. The OVAPBS solution was filtered sterilize through a 0.45 micron filter, and was then diluted with
1:1 (ml:ml) Freund’s incomplete adjuvant (ThermoFisher Scientific, Waltham, MA). The
OVA-PBS-Freunds solution was emulsified using a 22 gauge micro-emulsifying needle
and glass mixing syringes for several minutes. The OVA vaccine was transferred to
plastic 5 mL syringes with 18 gauge needles for administration to calves. The vaccine
was made weekly and stored in refrigerator for up to four days before administration.
Nasal Secretion Collection and Analysis
Nasal secretion samples were collected from calves twice throughout the study.
Secretion samples were collected when the calves arrived (0 d) before vaccination of
Inforce 3 via intranasal (Zoetis; Florham Park, NJ), and again on week three (21 d). A 50
x 55 mm foam plug (VWR, Radnor, PA) was cut into quarters and one quarter was
inserted into the nasal cavity of the calf and was allowed to sit for 5 to 7 minutes or until
the foam was saturated. The foam was then pulled out and inserted into a 10 mL plastic
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syringe that was used to squeeze the nasal secretions out into a 1 mL microcentrifuge
tube that was then stored frozen (-20ºC) until analysis.
Nasal secretions were analyzed for specific IgA titers to Inforce 3 against
bovine respiratory syncytial virus (BRSV) using an enzyme-linked immunosorbent assay
(ELISA) modified from Woolums et al. (2013). Samples were prepared using a 96-round
well plate (Immulon 1B, VWR, Radnor, PA). Every other column of the plate was coated
by pipetting 100 µL/well of a 1:10 dilution of UV inactivated BHV-1 Cooper strain.
Stock solution of BHV-1 Cooper strain had a titer of 1 X 107 TCID 50/ml and was
inactivated by placing in a hood with UV for 20 minutes which was stored at -80ºC until
ready to use for coating. Prior to coating the UV inactivated BHV-1 Cooper strain was
diluted 1:10 with a coating buffer which was distilled water containing 0.9% sodium
carbonate (Sigma Chemical, St. Louis, MO) solution adjusted to a pH of 9.7. The noncoated (no BHV-1 Cooper strain) columns served as a control to account for non-specific
binding. All stock solutions were made fresh the day samples were analyzed. Plates were
allowed to incubated at 4ºC for at least 12 h (overnight) before analysis, to allow
adherence of antigen to each coated well. Following overnight incubation plates were
emptied and washed once with phosphate buffered saline tween (washing buffer) and 200
µL of blocking buffer solution was added to each well and allowed to incubate for 1h at
room temperature (~22ºC). Phosphate buffered saline tween (PBST) was prepared as
PBS with 0.05% of polyoxeyethylene sorbitan monolaurate (Tween 20, Sigma Chemical,
St. Louis, MO). The blocking solution was prepared with phosphate buffer solution
(PBS) that contained 0.5% bovine serum albumin (BSA, Sigma Chemical, St. Louis,
MO). Following incubation of the blocking buffer, plates were emptied and washed 3
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times with PBST and blotted dry. Nasal secretion samples were thawed and diluted in a
two-fold serial dilatation with PBST that contained 0.01% bovine serum albumin (BSA,
Sigma Chemical, St. Louis, MO). Dilution of nasal secretion samples from initial
concentration was 1/4 for both week 0 (d 0) and week 3 (21 d). One hundred µL of the
diluted samples were added to the wells in duplicate and incubated for 1 h at room
temperature (~22ºC). Following incubation plates were emptied and washed 4 times with
PBST wash buffer and blotted dry. A second antibody, rabbit anti-bovine IgA (Bethyl
Laboratories Inc., Montgomery, TX) was diluted to a concentration of 1:2500 with PBST
containing 0.01% BSA and 100 µL was pipetted to each well and incubated for 1 h at
room temperature (~22ºC). Following incubation plates were emptied and washed 4
times with PBST wash buffer and blotted dry. A tetramethylbenzidine substrate solution
(TMB, ThermoFisher Scientific, Waltham, MA) was added at 100 µL per well and
incubated in the dark at room temperature (~22ºC) for 20 minutes for color development.
The reaction was stopped by adding 100 µL of a TMB stop solution to each well. Plates
were then read at 405 nm optical wavelength using a 96-well plate reader (Biotek,
ELx808, Winooski, VT).
Body, Fecal and Health Measurements
Body weights were taken weekly using a digital scale (Digi-Star, Fort Atkinson,
WI) after morning feeding. Body measurements including wither height (WH), hip
height (HH), hip width (HW), heart girth (HG) and body length (BL) were taken biweekly at the time body weights were taken.
Fecal samples were collected three times for each calf throughout the trial and
were taken when they first arrived (0 d) and then the beginning of week two (8 d) and
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week five (35 d). Samples were taken fresh to Rural Technologies Inc. (Brookings, SD)
for analysis of Escherichia coli, Salmonella, Clostridium, and Cryptosporidium. Samples
were analyzed using a streak plate and given semi quantitative descriptions based on
growth of the bacteria into different quadrants of the plate. Escherichia coli descriptions
were established as 1) none detected, 2) Rare amount, 1 phenotype, 3) rare amount, 2
phenotypes, 4) small amount, 1 phenotype, 5) small amount, 2 phenotypes, 6) moderate
amount, 1 phenotype, 7) moderate amount, 2 phenotypes, 8) moderate amount, 3
phenotypes, 9) large amount, 1 phenotype, 10) large amount, 2 phenotypes, 11) large
amount, 3 phenotypes. Salmonella, Clostridium, and Cryptosporidium descriptions: 1)
none detected, 2) rare amount present, 3) small amount present, 4) few present, 5)
moderate amount present, 6) large amount present, 7) many present.
Health scores included ear, eye, nasal, and fecal scores and were recorded daily
before evening feeding. Health scores were according to the University of Wisconsin calf
health scoring chart (McGuirk, 2013), and were based on a 0-3 scale. Fecal scores were
established as 0) normal, 1) semi-formed, pasty, 2) loose, but stays on top of bedding, 3)
watery, sifts through bedding. Ear scores: 0) normal, 1) ear flick or head shake, 2) slight
unilateral droop, 3) head tilt or bilateral droop. Eye scores: 0) normal, 1) small amount of
ocular discharge, 2) moderate amount of bilateral discharge, 3) heavy ocular discharge.
Nasal scores: 0) normal serous discharge, 1) small amount of unilateral cloudy discharge,
2) bilateral, cloudy or excessive mucus discharge, 3) copious bilateral mucopurulent
discharge. All health incidents, and treatments were recorded for the length of the study.
Blood Sampling and Analysis
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Blood samples were collected from the jugular vein on all calves weekly after
morning feeding. Blood samples were collected using a 10 ml Vacutainer serum
separation tube with a 18 gauge needle (Animal Health International, Greenly, CO).
Samples were allowed to clot, and serum was harvested by centrifugation at 2,000 x g for
20 min and stored frozen in 5 ml polystyrene tubes for later analysis.
VFA- Serum samples from week 5 were analyzed for VFA concentrations using a
GC (model 6850, Agilent, Santa Clara, CA). Samples were prepared according to the
procedures of Oba and Allen (2003) and 1 µL of sample was injected at a split ratio of
2:1 at the injection port (280ºC). Volatile fatty acids were separated on a capillary column
(30 m x 0.32 mm x DB 0.25; Agilent, Santa Clara, CA) with a flow of 45 mL/min of He
using 2-ethylbutyrate as an internal standard. Initial oven temperature was 90ºC for 5 min
and then was increased by 10ºC/min to 150ºC, where it was held for 5 min. The oven was
brought up to 170ºC for purging at the end of the run. The flame ionization detector was
maintained at 300ºC.
ELISA Ovalbumin Assay- Serum samples from week 3, 4, 5, 6, 7, and 8 were
analyzed for determination of IgG titers to vaccination of calves with ovalbumin using a
modified protocol from Rivera et al. (2002). Samples were prepared using a 96-round
well plate (Immulon 1B, VWR, Radnor, PA). Every other column of the plate was coated
by pipetting 100 µL of a solution containing 0.005 mg of ovalbumin/mL of PBS or 500
ng of ovalbumin per well. The non-coated (no ovalbumin) columns served as a control to
account for non-specific binding. All stock solutions were made fresh the day samples
were analyzed. Plates were allowed to incubated at 4ºC for at least 12 h (overnight)
before analysis, to allow adherence of ovalbumin antigen to each coated well. Following

31

overnight incubation plates were emptied and 200 µL of a blocking buffer solution was
added to each well and allowed to incubate for 1 h at room temperature (~22ºC). The
blocking solution contained PBST with 2% Casein (Sigma Chemical, St. Louis, MO).
PBST was prepared as PBS with 0.05% of polyoxeyethylene sorbitan monolaurate
(Tween 20, Sigma Chemical, St. Louis, MO). Following incubation of the blocking
buffer, plates were emptied and washed 3 times with PBST and blotted dry. Serum
samples were thawed and diluted in a two-fold serial dilution with PBST that contained
0.1% bovine serum albumin (BSA, Sigma Chemical, St. Louis, MO). Dilution of serum
samples were as followed week 3 (21 d) and 4 (28 d) were diluted 1/4 from initial
concentration, week 5 (35 d) diluted 1/16, week 6 (42 d) diluted 1/64, week 7 (49 d) and
8 (56 d) diluted 1/512 from initial concentration. One hundred µL of the diluted samples
were added to the wells in duplicate and incubated for 1 h at room temperature (~22ºC).
Following incubation plates were emptied and washed 3 times with PBST wash buffer
and blotted dry. A second antibody, alkaline phosphatase anti-bovine IgG (Sigma
Chemical, St. Louis, MO) was diluted to a concentration of 1:5000 in PBST containing
0.1% BSA and 100 µL was pipetted to each well and incubated for 1 h at room
temperature (~22ºC). Following incubation plates were emptied and washed 3 times with
PBST wash buffer and blotted dry. A substrate solution was added at 200 µL per well and
incubated in the dark at room temperature (~22ºC) for 13 min. Substrate solution was
made fresh prior to addition to wells and was made by using SIGMAFAST p-nitrophenyl
phosphate tablets (Sigma Chemical, St. Louis, MO) added to diethanolamine substrate
buffer (ThermoFisher, Waltham, MA) that was diluted from 5x concentration to 1x with
distilled water. The reaction was stopped by adding 50 µL of a 2 M NaOH solution to

32

each well. Plates were then read at 405 nm optical wavelength using a 96-well plate
reader (Biotek, ELx808, Winooski, VT).
Statistical Analysis
All data were subjected to least squares ANOVA for a randomized complete
block design using the PROC MIXED procedure of SAS (version 9.3, SAS Institute Inc.,
Cary, NC). Calves were blocked by birth date. Treatment, week, and treatment x week
were considered to be fixed effects, with calf within treatment as random effect. Least
squares means were separated by PDIFF. Body weights, and measurements were adjusted
by the covariate to account for difference in initial measurements. IgA and IgG titers
were determined by subtracting control wells (non-coated) from corresponding optical
density reading for the value of the sample well (coated) to account for non-specific
binding. Fecal pathogen descriptions were grouped into 1) none detected, 2) rare amount,
3) small amount, 4) moderate amount, 5) large amount for Escherichia coli and 1) none
detected, 2) rare/small present, 3) few/moderate present, 4) large/many present for
Salmonella, Clostridium, and Cryptosporidium. Significance was declared at P < 0.05
and trends at 0.05 < P < 0.10. Dry matter intake, fecal, nasal, eye, an ear scores were
averaged by week. Means for the remaining variables were calculated from the data
gathered during the collection time for each period.
RESULTS AND DISCUSSION
Feed Analysis
Nutrient composition and DM of MR and CS are provided in Table 1. The 20:24
MR slightly exceeded the for CP formulation specification. However, the fat was slightly
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below the formulation specification (19.5% compared to 20%) but still is adequate for
neonatal calves. The CS met or exceed formulation requirements for nutrients.
Immunological Performances
Immunoglobulin A titers were similar (P > 0.10) among all treatments (Table 2
and Figure 1). However, numerically calves fed EO-0.5 had higher IgA titers compared
to calves fed the other treatments, and calves fed EO-1.0 and EO-1.5 had the lowest
titers.
Immunoglobulin G titers were similar between treatments for week 3, 4, 5, and 6
(Table 2 and Figure 2). It was not until the booster ovalbumin vaccine was given during
week 6 that numerical differences could be observed. Statistically, calves fed EO-1.0 and
EO-1.5 had the lowest titers compared to calves fed C, EO-0.5 and YCW for weeks 7 and
8. Similarly to IgA results calves fed EO-0.5 had the highest IgG titer values.
Calves fed the EO-0.5 had the greatest immunological response. Too much of an
immunological response can be detrimental to a growing calf because of the energy
expenditure needed. However, in this case calves fed EO-0.5 had improved growth rates
compared to other treatments (Table 5) as well as an improved immunological response,
indicating that the EO-0.5 improved the immunity of the calves. Calves fed EO-1.0 and
EO-1.5 had the lowest titer results compared to C, YCW, and EO-0.5 indicating that the
immune system was possibly overwhelmed and was shut down as a protective response.
As an overactive immune system response could lead to self-damage from inflammation,
a properly working immune system can be thought of as a teeter totter. An
immunological response is great when a challenge arrives but too much of a response will
result in self-inflicted damages (Mak et al., 2014).
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Health Performances and Fecal Pathogens
Total serum blood protein averaged 6.5 ± 0.15 g/dl (Table 3). The mean serum
protein levels were not different between treatments and were above 5.5 g/dl indicating
successful passive transfer of immunity.
Health scores were averaged weekly for the 56 d study (Table 3). Overall health
scores were acceptable for all calves across all treatments. Fecal scores (Table 3 and
Figure 3) on weeks one, five, seven, and eight were similar (P > 0.05) for calves fed all
treatments. Fecal scores were higher on week two for calves fed C compared to calves
fed EO-1.0, and were significantly greater for calves fed C compared to calves fed EO0.5 and YCW on week three. During week four, calves fed EO-1.5 had significantly (P <
0.05) higher fecal scores compared to calves fed C and EO-0.5. Again on week six fecal
scores were significantly (P > 0.05) greater for calves fed EO-1.5 compared to calves fed
EO-1.0. There were some significant differences in nasal, ear, and eye scores (P < 0.05)
among some treatments, but the differences were small and calves were healthy overall.
Fecal pathogens were analyzed for samples that were collected on 0, 8, and 35 d
(Table 4.) Analysis of fecal pathogens indicated no detection of salmonella throughout
the study with no treatments differences in clostridium and cryptosporidium when the
calves first arrived for the trial (0 d). Calves fed the control treatment had higher (P <
0.05) cryptosporidium levels on d 8 compared to calves fed the other treatments, but by d
35 no difference were observed between treatments. Clostridium was significantly (P <
0.05) increased for calves fed EO-0.5 compared to calves fed control on 8 d.
Numerically, by 35 d calves fed EO had lower clostridium levels than calves fed YCW
and C and EO-1.0 fed calves were significantly (P < 0.05) lower compared to calves fed
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YCW and C. Escherichia coli was significantly higher for YCW calves than EO-1.5 fed
calves on 0 d of the trial but by 8 and 35 d no significant differences were detected.
Body Growth and Measurements
Initial, final, and total gains of body weight and body measurements are shown in
Table 5. The mean initial body weight (BW) of all the calves was 38.9 ± 1.5 kg. Calves
fed EO-1.0 and EO-1.5 had significantly (P < 0.05) different initial body weights at the
start of the trial, with no significant (P > 0.10) differences among the other treatments.
All data were covariate adjusted to minimize pretreatment differences. Total BW gain
and final BW were increased for calves fed EO-0.5 compared to calves fed EO-1.0,
YCW, and C. Calves fed EO-0.5 demonstrated greater (P < 0.05) ADG through 56 d
compared to calves fed EO-1.0 and YCW, while tending (P < 0.10) to be greater for
calves fed C and EO-1.5. These growth measurements are industry acceptable with calves
doubling their starting body weight by eight weeks. These growth measurements are also
exceptional compared to a similar study by Santos et al., (2015) who fed lower amounts
of EO but similar amounts of MR. In that study, Santos et al., (2015) reported an ADG of
.38 kg for calves supplemented with a blend of EO (0.4 g/kg).
Calves fed EO-1.0 had significantly (P < 0.05) greater initial BL and HG
compared to calves fed C, but similar to calves assigned to the other treatments. Calves
fed EO-1.0 had significantly (P < 0.05) greater initial WH compared to calves fed YCW,
but similar to calves assigned to the other treatments. Initial HH and HW measurements
were similar for calves assigned to all treatments. Numerically, by the end of the study,
calves fed EO-0.5 had the greatest body measurement gains. Calves fed EO-0.5 were
significantly (P < 0.02) greater than calves fed EO-1.5 in BL gains. Gains in HW were
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greater for calves fed EO-0.5 compared to calves fed C, but were similar among the
remaining treatments. Gains of WH through 56 d was greater for calves fed EO-0.5
compared to calves C, EO-1.0, EO-1.5, while being similar for calves fed YCW. Gains in
HH were greater for calves fed EO-0.5 compared to calves fed C, EO-1.0, EO-1.5 and
YCW. Gains in HG calves fed C were significantly increased compared to calves fed
YCW, however, calves fed EO-0.5 had the highest numerical HG gains while calves fed
EO-1.5 had the lowest numerical gains. The reasons for these values not showing up
significantly different is attributed to the standard errors of the samples being less than
that of the other treatments. This data demonstrates that feeding EO-0.5 (1.25 g/calf/d) to
a 24:20 MR will enhance growth rates compared to calves fed a modified accelerated
24:20 MR and a 24:20 MR containing YCW technology.
Volatile Fatty Acids
Serum blood samples from week five were analyzed for volatile fatty acids (VFA)
as an indirect measurement of rumen development (Table 6). Quigley et. al., (1990)
found that differences in plasma VFA were greatest between five and eight weeks of age
in calves that were weaned early (28 d) and late weaned calves (56 d). Week five was the
start of weaning and the blood VFA concentrations were similar between all treatments.
Blood concentrations of isobutyrate and valerate were below detection limits. There was
no significant difference (P > 0.10) in propionate and butyrate concentrations between
treatments. These results are similar to data reported by Santos et al., (2015) who found
no significant differences in propionate, butyrate, and acetate in calves supplemented
with and without EO. Calves fed YCW were significantly lower in acetate concentration
compared to calves fed C, EO-0.5, EO-1.0, and EO-1.5. Calves fed YCW were
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significantly lower in isovalerate concentration compared to calves fed EO-1.0 and EO1.5, but were similar in concentration to C and EO-0.5 calves. The VFAs are known to
initiate epithelial and papillary growth within the rumen and butyrate is considered the
most effective followed by propionate and acetate (Sakate and Tamate, 1979). Based on
this knowledge it can be concluded that the treatments in this study neither inhibited nor
enhanced ruminal development.
Dry matter intake, feed efficiency
Calf starter intake on a dry matter basis had no significant (P > 0.10) differences
among treatments during the initial four weeks (Figure 5 and Table 7). The start of
weaning (week five) calves fed EO-0.5 had significantly (P < 0.05) greater CS
consumption than calves fed YCW, which continued through week 7 and 8. During week
six, calves fed EO-1.0 had significantly greater CS intake compared to calves fed YCW,
while calves fed EO-0.5 had greater CS intake compared to calves fed C and YCW. Total
dry matter intake (MR plus CS) yielded similar results as CS DMI (Table 7). There were
no significant (P > 0.10) differences in gain per feed (feed efficiency) among the
different treatments (Table 7). Similar studies supplementing calves with EO have
reported varying results. In a study conducted by Santos et al., (2015) found that calves
supplemented with a blend of EO were similar in CS intake compared to nonsupplemented calves. However, these results are in contrast to data reported by Hill et al.,
(2007) that demonstrated a commercial blend of EO actually increased CS intake and
efficiency.
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CONCLUSIONS
In this study the hypothesize proved partly true. Dairy calves supplemented with a
commercial EO performed well compared to non-supplemented calves. However, dairy
calves fed EO-0.5 demonstrated the optimal response compared to the hypothesized EO1.0. Body weight, measurements, and ADG gains were numerically higher for EO-0.5
then calves fed C, YCW, and higher doses of essential oils. Similarly, calves fed EO-0.5
had the highest numerical IgA and IgG titers corresponding well with growth
performance data indicating healthier calves. Calves fed EO-0.5 compared to C calves
had significantly higher HG, WH, HH, WH, and BW gains. Furthermore, blood VFA
concentrations were similar among treatments, indicating that the EO neither inhibited
nor enhanced ruminal development. Health scores among treatments were acceptable and
calves supplemented with EO were neither healthier or sicker compared to calves fed the
other treatments. In some weeks, calves supplemented with EO numerically had
improved fecal scores compared to calves fed C and YCW.
Overall, calves benefit with supplementation of a commercial EO. Questions still
remain and future direction would be to see if a different dosage of this commercial EO
could improve immunological, and growth of calves even more either through a lower
dose or possibly a slightly higher (but lower than EO-1.0) dose. Other potential options
would be to see if there is any benefit of feeding EO in the solid feed (pellets) of calves
for an extended period of time that would extend past weaning.
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Table 1. Milk replacer and calf starter nutrient analysis
Item1
DM, %
Crude Protein, %
ADF, %
Fat, %
Starch, %
Ash, %
Calcium, %
Phosphorus, %
Magnesium, %
Mcal, kcal/kg
1

Milk Replacer
95.6
26.0
0.93
19.5
0.93
9.87
0.94
0.72
0.14
2730.9

Nutrient analysis conducted by Analabs (Fulton, IL). Values are reported as % DM.

Calf Starter
87.3
23.5
12.0
3.3
21.5
7.5
0.85
0.61
0.38
2097.3
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Table 2. Immunological titers
Treatments1
Item
No. calves

C
20

EO-0.5
20

EO-1.0
20

EO-1.5
19

YCW
20

SEM

8.2
17.3

7.7
26.5

2.8
17.1

4.6
19.9

5.3
17.9

4.1
4.6

10.1
30.8
178.1
411.2
4536.4ac
4224.7ab

7.5
10.3
141.3
441.0
5058.5ac
5310.0ab

7.3
19.9
166.7
405.4
2602.6bc
2339.6c

10.2
7.3
78.9
270.9
1956.8b
2192.1c

5.7
9.4
142.6
405.9
4037.0ac
3684.2b

597.0
597.0
613.3
597.0
597.0
597.0

IgA
0d
21 d
IgG
21 d
28 d
35 d
42 d
49 d
56 d
1

Control (C): 24:20; EO-0.5: 24:20 MR with 1.25 g Stay Strong added; EO-1.0: 24:20 MR with 2.5 g Stay Strong
added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g Bio-Moss added. All MR
were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then fed 1x/d from 36 d to weaning at 42
d.

41

Table 3. Total serum proteins and health scores
Treatments1
EO-0.5
EO-1.0
20
20
6.50
6.56

Item
C
EO-1.5
YCW
SEM
20
19
20
No. calves
6.40
6.43
6.62
0.21
Serum Protein
Fecal Scores2
1 to 7 d
1.09
1.19
1.22
1.27
1.18
0.08
8 to 14 d
2.01a
1.83ab
1.75b
1.84ab
1.93ab
0.08
15 to 21 d
1.28a
0.97bc
1.05abc
1.13abc
1.08bc
0.08
22 to 28 d
0.33b
0.38b
0.45ab
0.58a
0.40ab
0.08
29 to 35 d
0.21
0.20
0.23
0.24
0.24
0.08
36 to 42 d
0.19ab
0.15ab
0.05b
0.28a
0.09ab
0.08
43 to 49 d
0.10
0.07
0.06
0.005
0.09
0.08
50 to 56 d
0.05
0.03
0.03
0.03
0.02
0.08
Nasal Scores3
1 to 7 d
0.05
0.06
0.06
0.07
0.05
0.02
8 to 14 d
0.01b
0.01b
0.05b
0.14a
0.02b
0.02
15 to 21 d
0
0.01
0.03
0.05
0.03
0.02
22 to 28 d
0b
0.07a
0.07a
0.05ab
0.06ab
0.02
29 to 35 d
0.02
0.06
0.03
0.01
0.03
0.02
36 to 42 d
0
0.03
0.02
0.04
0.01
0.02
43 to 49 d
0.07
0.01
0.02
0.06
0.04
0.02
50 to 56 d
0.01b
0.02b
0.03ab
0.08a
0.01b
0.02
Eye Scores4
1 to 7 d
0.03
0.04
0.08
0.10
0.04
0.05
8 to 14 d
0.06
0.06
0.06
0.07
0.10
0.05
15 to 21 d
0.26
0.18
0.27
0.29
0.30
0.05
22 to 28 d
0.31a
0.15b
0.21ab
0.22ab
0.24ab
0.05
29 to 35 d
0.17b
0.19b
0.35a
0.23ab
0.14ab
0.05
36 to 42 d
0.18ab
0.18ab
0.27a
0.19ab
0.12b
0.05
43 to 49 d
0.17
0.20
0.17
0.18
0.27
0.05
50 to 56 d
0.25
0.23
0.27
0.27
0.24
0.05
Ear Scores5
1 to 7 d
0.42bc
0.42bc
0.53abc
0.59ac
0.61a
0.06
8 to 14 d
0.75
0.63
0.59
0.61
0.65
0.06
15 to 21 d
0.65
0.63
0.65
0.71
0.58
0.06
22 to 28 d
0.68a
0.67a
0.61ab
0.44b
0.61ab
0.06
29 to 35 d
0.67a
0.43b
0.62a
0.46b
0.53ab
0.06
36 to 42 d
0.47
0.42
0.43
0.51
0.58
0.06
43 to 49 d
0.41
0.39
0.47
0.42
0.37
0.06
50 to 56 d
0.37
0.31
0.28
0.24
0.41
0.06
1
Control (C): 24:20; EO-0.5: 24:20 MR with 1.25 g Stay Strong added; EO-1.0: 24:20 MR with 2.5 g Stay
Strong added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g Bio-Moss added.
All MR were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then fed 1x/d from 36 d to
weaning at 42 d.
2
Fecal score = 0 to 3; 0 = normal, ≥ 2 = scours
3
Nasal score = 0 to 3; 0 = normal, 3 = excessive mucopurulent discharge
4
Eye score = 0 to 3; 0 = normal, 3 = heavy ocular discharge
5
Ear score = 0 to 3; 0 = normal, 3 = droopy
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Table 4. Fecal pathogens
Treatments1
Item

C

EO-0.5

EO-1.0

EO-1.5

YCW

SEM

No. calves

20

20

20

19

20

---

0d

4.3ab

4.2ab

4.3ab

4.0b

4.5a

0.3

8d

3.8

3.9

3.8

3.8

4.1

0.5

35 d

3.8

3.1

3.2

3.1

3.1

0.4

0d

ND

ND

ND

ND

ND

---

8d

ND

ND

ND

ND

ND

---

35 d

ND

ND

ND

ND

ND

---

0d

1.4

1.6

1.7

1.5

1.6

0.3

8d

b

a

Escherichia coli2

Salmonella3

Clostridium4

35 d

1.0

a

1.3

1.4

ab

1.2

ab

1.4

b

1.1

a

1.2

ab

1.2

ab

0.2

1.4

a

0.2

1.3

Cryptosporidium5
0d

1.0

1.1

1.0

1.0

1.0

0.0

8d

2.2a

1.8ab

1.5ab

1.5ab

1.6b

0.4

35 d

1.0

1.1

1.1

1.0

1.1

0.1

1

Control (C): 24:20; EO-0.5: 24:20 MR with 1.25 g Stay Strong added; EO-1.0: 24:20 MR with 2.5 g Stay Strong
added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g Bio-Moss added. All MR
were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then fed 1x/d from 36 d to weaning at
42 d.
2
Escherichia coli = 1 to 5; 1 = absent, 5 = large amount present
3
Salmonella = 1 to 4; 1 = absent, 4 = large amount present
4
Clostridium = 1 to 4; 1 = absent, 4 = large amount present
5
Cryptosporidium = 1 to 4; 1 = absent, 4 = large amount present
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Table 5. Body weight, measurements, ADG
Treatments1
Item

C

EO-0.5

EO-1.0

EO-1.5

YCW

SEM

No. calves

20

20

20

19

20

Initial

38.1ab

39.2ab

41.1a

37.0b

38.9ab

3.4

Final

75.7b

79.2a

72.1b

74.7ab

74.4b

6.4

Gain

b

a

35.5

b

ab

b

6.4

0.71

0.64

b

0.63

b

0.08

BW, kg

ADG, kg

36.8
0.65

ab

39.9

a

35.8

ab

0.64

35.4

BL, cm
Initial

62.52b

63.99ab

64.49a

63.47ab

62.77ab

1.09

Final

76.62ab

78.16a

76.58ab

75.63b

76.67ab

1.06

Gain

13.11ab

14.66a

13.08ab

12.12b

13.17ab

1.06

Initial

77.10b

79.48ab

80.26a

77.74ab

79.0ab

1.20

Final

98.12b

98.45ab

96.52bc

96.42bc

96.57c

0.80

Gain

19.30b

19.68ab

17.70bc

17.60bc

17.75c

0.80

Initial

75.43ab

76.08ab

77.09a

74.96ab

74.89b

1.03

Final

85.56b

87.13a

85.58b

85.18b

86.15ab

0.54

Gain

9.78b

11.34a

9.80b

9.40b

10.36ab

0.54

Initial

79.87

80.21

81.98

79.75

79.73

1.02

Final

90.58b

92.58a

90.0b

90.20b

90.97b

0.73

Gain

10.13b

12.13a

9.56b

9.77b

10.52b

0.73

Initial

46.29

47.31

47.47

46.71

46.92

1.57

Final

69.18

b

a

22.18

b

HG, cm

WH, cm

HH, cm

HW, cm

Gain
1

71.76
24.76

a

69.62

ab

22.62

ab

ab

69.38
22.38

ab

ab

1.52

ab

1.52

69.47
22.47

Control (C): 24:20; EO-0.5: 24:20 MR with 1.25 g Stay Strong added; EO-1.0: 24:20 MR with 2.5 g
Stay Strong added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g
Bio-Moss added. All MR were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR
then fed 1x/d from 36 d to weaning at 42 d.
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Table 6. Volatile Fatty Acids
Treatments1
Item

C

EO-0.5

EO-1.0

EO-1.5

YCW

SEM

Acetate, mM

0.64a

0.61a

0.60a

0.61a

0.48b

0.06

Propionate, mM

0.05

0.04

0.07

0.06

0.03

0.01

Isobutyrate, mM

ND

ND

ND

ND

ND

Butyrate, mM

0.06

0.07

0.07

0.06

0.06

0.01

0.002ab

0.004ab

0.006a

0.007a

0.001b

0.002

ND

ND

ND

ND

ND

Isovalerate, mM
Valerate, mM
1

Control (C): 24:20; EO-0.5: 24:20 MR with 1.25 g Stay Strong added; EO-1.0: 24:20 MR with 2.5 g Stay Strong added; EO-1.5: 24:20 MR with 3.75 g
Stay Strong added; YCW: 24:20 MR with 2 g Bio-Moss added. All MR were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then fed
1x/d from 36 d to weaning at 42 d.
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Table 7. CS DMI, Total DMI, Gain per Feed
Treatments1
Item
C
EO-0.5
EO-1.0
EO-1.5
20
20
20
19
No. calves
CS DMI, kg/d
1 to 7 d
0.02
0.01
0.01
0.02
8 to 14 d
0.05
0.05
0.05
0.05
15 to 21 d
0.13
0.18
0.16
0.18
22 to 28 d
0.29
0.33
0.28
0.33
29 to 35 d
0.46ab
0.58a
0.54ab
0.52ab
36 to 42 d
0.97bc
1.17ac
1.07ac
1.04abc
ab
a
ab
43 to 49 d
1.84
1.90
1.86
1.87ab
50 to 56 d
2.25ab
2.31a
2.17ab
2.19ab
Total DMI,
kg/d
1 to 7 d
0.55
0.55
0.55
0.55
8 to 14 d
0.58
0.59
0.58
0.59
15 to 21 d
0.95
1.00
0.98
1.00
22 to 28 d
1.11
1.15
1.10
1.16
29 to 35 d
1.27ab
1.40a
1.36ab
1.34ab
36 to 42 d
1.38bc
1.58a
1.48ab
1.45abc
43 to 49 d
1.85ab
1.90a
1.86ab
1.87ab
ab
a
ab
50 to 56 d
2.25
2.31
2.17
2.19ab
Gain per Feed
1 to 7 d
0.90
0.94
0.91
0.92
8 to 14 d
0.19
0.30
0.09
0.33
15 to 21 d
0.76
0.81
0.70
0.72
22 to 28 d
0.56
0.63
0.64
0.61
29 to 35 d
0.70
0.63
0.64
0.57
36 to 42 d
0.34
0.50
0.40
0.38
43 to 49 d
0.42
0.38
0.44
0.39
50 to 56 d
0.49
0.47
0.44
0.41
1

YCW
20

SEM

0.01
0.02
0.12
0.27
0.41b
0.90b
1.73b
2.14b

0.08
0.08
0.08
0.08
0.08
0.08
0.08
0.08

0.55
0.56
0.94
1.09
1.23b
1.31c
1.73b
2.14b

0.08
0.08
0.08
0.08
0.08
0.08
0.08
0.08

0.88
0.12
0.73
0.70
0.55
0.39
0.41
0.53

0.11
0.11
0.11
0.11
0.11
0.11
0.11
0.11

Control (C): 24:20; EO-0.5: 24:20 MR with 1.25 g Stay Strong added; EO-1.0: 24:20 MR with 2.5 g
Stay Strong added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g BioMoss added. All MR were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then
fed 1x/d from 36 d to weaning at 42 d.
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Figure 1. IgA titers
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Stay Strong added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g BioMoss added. All MR were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then
fed 1x/d from 36 d to weaning at 42 d.
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Figure 2. IgG titers
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Stay Strong added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g BioMoss added. All MR were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then
fed 1x/d from 36 d to weaning at 42 d.
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Figure 3. Fecal scores
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Stay Strong added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g BioMoss added. All MR were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then
fed 1x/d from 36 d to weaning at 42 d.
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Figure 4. Body weight
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Stay Strong added; EO-1.5: 24:20 MR with 3.75 g Stay Strong added; YCW: 24:20 MR with 2 g BioMoss added. All MR were fed at 0.28 kg 2x/d for 14d, then 0.43 kg 2x/ d from 15 d to 35 d, MR then
fed 1x/d from 36 d to weaning at 42 d.
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Figure 5. Calf starter intake
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fed 1x/d from 36 d to weaning at 42 d.
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